首页> 外文期刊>Cancer research: The official organ of the American Association for Cancer Research, Inc >Zerumbone down-regulates chemokine receptor CXCR4 expression leading to inhibition of CXCL12-induced invasion of breast and pancreatic tumor cells.
【24h】

Zerumbone down-regulates chemokine receptor CXCR4 expression leading to inhibition of CXCL12-induced invasion of breast and pancreatic tumor cells.

机译:Zerumbone下调趋化因子受体CXCR4的表达,从而抑制CXCL12诱导的乳腺癌和胰腺肿瘤细胞的侵袭。

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

CXC chemokine receptor 4 (CXCR4), initially linked with leukocyte trafficking, is now known to be expressed in various tumors including breast, ovary, prostate, gastrointestinal, head and neck, bladder, brain, and melanoma. This receptor mediates homing of tumor cells to specific organs that express the ligand CXCL12 for this receptor. Thus, agents that can down-regulate CXCR4 expression have potential against cancer metastasis. In this study, we report the identification of zerumbone, a component of subtropical ginger (Zingiber zerumbet), as a regulator of CXCR4 expression. This sesquiterpene down-regulated the expression of CXCR4 on HER2-overexpressing breast cancer cells in a dose- and time-dependent manner. The decrease in CXCR4 by zerumbone was found to be not cell type specific as its expression was abrogated in leukemic, skin, kidney, lung, and pancreatic cancer cell lines. The down-regulation of CXCR4 was not due to proteolytic degradation but rather to transcriptional regulation, as indicated by down-regulation of mRNA expression, inhibition of nuclear factor-kappaB activity, and suppression of chromatin immunoprecipitation activity. Suppression of CXCR4 expression by zerumbone correlated with the inhibition of CXCL12-induced invasion of both breast and pancreatic cancer cells. An analogue of zerumbone, alpha-humulene, which lacks the carbonyl group, was found to be inactive in inducing CXCR4 down-regulation. Overall, our results show that zerumbone is a novel inhibitor of CXCR4 expression and thus has a potential in the suppression of cancer metastasis.
机译:CXC趋化因子受体4(CXCR4)最初与白细胞运输有关,现在已知在各种肿瘤中表达,包括乳腺癌,卵巢癌,前列腺癌,胃肠道癌,头颈癌,膀胱癌,脑癌和黑素瘤。该受体介导肿瘤细胞向表达该受体的配体CXCL12的特定器官的归巢。因此,可以下调CXCR4表达的药物具有抗癌转移的潜力。在这项研究中,我们报告鉴定了亚热带生姜(Zingiber zerumbet)的组成部分zerumbone,作为CXCR4表达的调节剂。该倍半萜烯以剂量和时间依赖性方式下调了HER2过表达的乳腺癌细胞上CXCR4的表达。发现在血清,皮肤,肾脏,肺和胰腺癌细胞系中,其表达已被废除,因此由蛇骨蛋白引起的CXCR4减少不是特定细胞类型。 CXCR4的下调不是由于蛋白水解降解,而是转录的调节,如mRNA表达的下调,核因子-κB活性的抑制和染色质免疫沉淀活性的抑制所表明的。 zerumbone抑制CXCR4表达与抑制CXCL12诱导的乳腺癌和胰腺癌细胞侵袭有关。发现缺少羰基的蛇骨酮类似物α-腐草烯在诱导CXCR4下调中没有活性。总体而言,我们的结果表明,蛇骨酮是CXCR4表达的新型抑制剂,因此具有抑制癌症转移的潜力。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号